Last reviewed · How we verify
ARGX-113
ARGX-113 is a monoclonal antibody that blocks the neonatal Fc receptor (FcRn) to reduce circulating immunoglobulin levels, particularly IgG antibodies.
ARGX-113 is a monoclonal antibody that blocks the neonatal Fc receptor (FcRn) to reduce circulating immunoglobulin levels, particularly IgG antibodies. Used for Generalized myasthenia gravis (gMG), IgG-mediated autoimmune conditions.
At a glance
| Generic name | ARGX-113 |
|---|---|
| Also known as | efgartigimod |
| Sponsor | argenx |
| Drug class | FcRn inhibitor |
| Target | FcRn (neonatal Fc receptor) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By binding to FcRn, ARGX-113 prevents the recycling and extends the catabolism of IgG antibodies, leading to rapid and sustained reduction in pathogenic autoantibodies. This mechanism is designed to treat autoimmune conditions driven by IgG-mediated pathology, such as myasthenia gravis and other antibody-mediated disorders.
Approved indications
- Generalized myasthenia gravis (gMG)
- IgG-mediated autoimmune conditions
Common side effects
- Infection (including upper respiratory tract infection)
- Headache
- Fatigue
Key clinical trials
- A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (PHASE3)
- A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy (PHASE3)
- A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (PHASE3)
- A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (PHASE3)
- Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS (PHASE2)
- A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (PHASE2)
- A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) (PHASE3)
- A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARGX-113 CI brief — competitive landscape report
- ARGX-113 updates RSS · CI watch RSS
- argenx portfolio CI